Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses (2016 - 2025)

Arrowhead Pharmaceuticals' Accumulated Expenses history spans 16 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 26.56% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $14.3 million, up 26.56%, while the annual FY2025 figure was $90.4 million, 311.2% up from the prior year.
  • Accumulated Expenses reached $14.3 million in Q4 2025 per ARWR's latest filing, down from $90.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $90.4 million in Q3 2025 to a low of $3.0 million in Q4 2021.
  • Average Accumulated Expenses over 5 years is $27.4 million, with a median of $18.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: soared 1523.11% in 2022, then crashed 81.78% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $3.0 million in 2021, then skyrocketed by 1523.11% to $48.2 million in 2022, then plummeted by 81.78% to $8.8 million in 2023, then rose by 28.46% to $11.3 million in 2024, then grew by 26.56% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Accumulated Expenses are $14.3 million (Q4 2025), $90.4 million (Q3 2025), and $19.3 million (Q2 2025).